

# Snake venomomics of *Bothrops punctatus*, a semi-arboreal pitviper species from Antioquia, Colombia

*Bothrops punctatus* is an endangered, semi-arboreal pitviper species distributed in Panamá, Colombia, and Ecuador, whose venom is poorly characterized. In the present work, the protein composition of this venom was profiled using the 'snake venomomics' analytical strategy. Decomplexation of the crude venom by RP-HPLC and SDS-PAGE, followed by tandem mass spectrometry of tryptic digests, showed that it consists of proteins assigned to at least nine snake toxin families. Metalloproteinases are predominant in this secretion (41.5% of the total proteins), followed by C-type lectin/lectin-like proteins (16.7%), bradykinin-potentiating peptides (10.7%), phospholipases A2 (9.3%), serine proteinases (5.4%), disintegrins (3.8%), L-amino acid oxidases (3.1%), vascular endothelial growth factors (1.7%), and cysteine-rich secretory proteins (1.2%). Altogether, 6.6% of the proteins were not identified. In vitro, the venom exhibited proteolytic, phospholipase A2, and L-amino acid oxidase activities, as well as angiotensin-converting enzyme (ACE)-inhibitory activity, in agreement with the obtained proteomic profile. Cytotoxic activity on murine C2C12 myoblasts was negative, suggesting that the majority of venom phospholipases A2 likely belong to the acidic type, which often lack major toxic effects. The protein composition of *B. punctatus* venom shows a good correlation with toxic activities here and previously reported, and adds further data in support of the wide diversity of strategies that have evolved in snake venoms to subdue prey, as increasingly being revealed by proteomic analyses. (219 words)

# Snake venomics of *Bothrops punctatus*, a semi-arboreal pitviper species from Antioquia, Colombia

Maritza Fernández Culma <sup>1</sup>, Jaime Andrés Pereañez <sup>1,2</sup>, Vitelbina Núñez Rangel <sup>1,3</sup>  
Bruno Lomonte <sup>4\*</sup>

<sup>1</sup> Programa de Ofidismo/Escorpionismo, <sup>2</sup> Facultad de Química Farmacéutica, and

<sup>3</sup> Escuela de Microbiología, Universidad de Antioquia UdeA, Calle 70 No.52-21, Medellín,

Colombia; <sup>4</sup> Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa

Rica, San José 11501, Costa Rica

Running title: Snake venomics of *Bothrops punctatus*

Keywords: Snake venom, Viperidae, proteomics, *Bothrops punctatus*

\* Corresponding author:

Bruno Lomonte, PhD  
Professor  
Instituto Clodomiro Picado  
Facultad de Microbiología  
Universidad de Costa Rica  
San José 11501, COSTA RICA  
[bruno.lomonte@ucr.ac.cr](mailto:bruno.lomonte@ucr.ac.cr)

## 14 ABSTRACT

15 *Bothrops punctatus* is an endangered, semi-arboreal pitviper species distributed in  
16 Panamá, Colombia, and Ecuador, whose venom is poorly characterized. In the present work, the  
17 protein composition of this venom was profiled using the 'snake venomomics' analytical strategy.  
18 Decomplexation of the crude venom by RP-HPLC and SDS-PAGE, followed by tandem mass  
19 spectrometry of tryptic digests, showed that it consists of proteins assigned to at least nine snake  
20 toxin families. Metalloproteinases are predominant in this secretion (41.5% of the total proteins),  
21 followed by C-type lectin/lectin-like proteins (16.7%), bradykinin-potentiating peptides (10.7%),  
22 phospholipases A<sub>2</sub> (9.3%), serine proteinases (5.4%), disintegrins (3.8%), L-amino acid oxidases  
23 (3.1%), vascular endothelial growth factors (1.7%), and cysteine-rich secretory proteins (1.2%).  
24 Altogether, 6.6% of the proteins were not identified. *In vitro*, the venom exhibited proteolytic,  
25 phospholipase A<sub>2</sub>, and L-amino acid oxidase activities, as well as angiotensin-converting enzyme  
26 (ACE)-inhibitory activity, in agreement with the obtained proteomic profile. Cytotoxic activity on  
27 murine C2C12 myoblasts was negative, suggesting that the majority of venom phospholipases A<sub>2</sub>  
28 likely belong to the acidic type, which often lack major toxic effects. The protein composition of  
29 *B. punctatus* venom shows a good correlation with toxic activities here and previously reported,  
30 and adds further data in support of the wide diversity of strategies that have evolved in snake  
31 venoms to subdue prey, as increasingly being revealed by proteomic analyses.

32 (219 words)

## INTRODUCTION

The Chocoan forest lancehead, *Bothrops punctatus*, known in Colombia as 'rabo de chucha', is a large semi-arboreal pitviper, ranging from 1.0 to 1.5 m in length. [Campbell & Lamar \(2004\)](#) described its distribution from the Pacific foothills and coastal plain of eastern Panamá through western Colombia to northwestern Ecuador, with an altitudinal range between 1350 and 2300 m. In Colombia, [Daza et al. \(2005\)](#) reported the occurrence of *B. punctatus* in the Cauca and Magdalena river basins of Antioquia to eastern Chocó. Although *Bothrops* species are clearly predominant in the epidemiology of snakebite accidents occurring in Colombia ([Otero, 1994](#); [Paredes, 2012](#)), published reports of proven envenomings caused by *B. punctatus* appear to be rare. The protein composition of the venom of this species has not been investigated, although at least two reports characterized its toxicological properties, in comparative studies of snake venoms from Colombia ([Otero et al., 1992](#)) and Ecuador ([Kuch et al., 1996](#)), respectively. The lethal potency of this venom to mice was highest among the different *Bothrops* venoms analyzed in these two studies, being only second to that of *Crotalus durissus terrificus* venom ([Otero et al., 1992](#); [Kuch et al., 1996](#)). Due to the lack of knowledge on the venom composition of *B. punctata*, this work aimed at characterizing its proteomic profile using the 'snake venomomics' analytical strategy ([Calvete et al., 2007](#); [Calvete 2011](#)), in combination with the assessment of its enzymatic or toxic activities *in vitro*.

## METHODS

### Venom

Venom was obtained from two adult *Bothrops punctatus* specimens collected in the eastern region of the Department of Antioquia, and kept in captivity at the Serpentarium of Universidad de Antioquia, Medellín, Colombia, under institutional permission for Programa de Ofidismo/Escorpionismo. Venom samples were centrifuged to remove debris, pooled, lyophilized

and stored at  $-20^{\circ}\text{C}$ . In some functional assays, pooled venom obtained from more than 30 specimens of *Bothrops asper*, collected in the Departments of Antioquia and Chocó, was included for comparative purposes.

## Proteomic profiling

For reverse-phase (RP) HPLC separations, 2.5 mg of venom was dissolved in 200  $\mu\text{L}$  of water containing 0.1% trifluoroacetic acid (TFA; solution A), centrifuged for 5 min at  $15,000\times g$ , and loaded on a  $\text{C}_{18}$  column ( $250 \times 4.6$  mm, 5  $\mu\text{m}$  particle; Teknokroma) using an Agilent 1200 chromatograph with monitoring at 215 nm. Elution was performed at 1 mL/min by applying a gradient towards solution B (acetonitrile, containing 0.1% TFA), as follows: 0% B for 5 min, 0-15% B over 10 min, 15-45% B over 60 min, 45-70% B over 10 min, and 70% B over 9 min (*Lomonte et al., 2014*). Fractions were collected manually, dried in a vacuum centrifuge, and further separated by SDS-PAGE under reducing or non-reducing conditions, using 12% gels. Protein bands were excised from Coomassie blue R-250-stained gels and subjected to reduction with dithiothreitol (10mM) and alkylation with iodoacetamide (50 mM), followed by in-gel digestion with sequencing grade bovine trypsin (in 25 mM ammonium bicarbonate, 10% acetonitrile) overnight on an automated processor (ProGest Digilab), according to the manufacturer. The resulting peptide mixtures were analyzed by MALDI-TOF-TOF mass spectrometry on an Applied Biosystems 4800-Plus instrument. Peptides were mixed with an equal volume of saturated  $\alpha$ -CHCA matrix (in 50% acetonitrile, 0.1% TFA), spotted (1  $\mu\text{L}$ ) onto Opti-TOF 384-well plates, dried, and analyzed in positive reflector mode. Spectra were acquired using a laser intensity of 3000 and 1500 shots/spectrum, using as external standards CalMix-5 (ABSciex) spotted on the same plate. Up to 10 precursor peaks from each MS spectrum were selected for automated collision-induced dissociation MS/MS spectra acquisition at 2 kV, in positive mode (500 shots/spectrum, laser intensity of 3000). The resulting spectra were analyzed

using ProteinPilot v.4 (ABSciex) against the UniProt/SwissProt database using the Paragon® algorithm at a confidence level of  $\geq 95\%$ , for the assignment of proteins to known families. Few peptide sequences with lower confidence scores were manually searched using BLAST (<http://blast.ncbi.nlm.nih.gov>). Finally, the relative abundance of each protein (% of total venom proteins) was estimated by integration of the peak signals at 215 nm, using Chem Station B.04.01 (Agilent). When a peak from HPLC contained two or more SDS-PAGE bands, their relative distribution was estimated by densitometry using the Image Lab v.2.0 software (Bio-Rad) (*Calvete, 2011*).

## **Venom activities**

### **Phospholipase A<sub>2</sub> activity**

Venom phospholipase A<sub>2</sub> (PLA<sub>2</sub>) activity was determined on the monodisperse synthetic substrate 4-nitro-3-octanoyl-benzoic acid (NOBA) (*Holzer and Mackessy, 1996*), in triplicate wells of microplates. Twenty  $\mu\text{L}$  of venom solutions, containing 20  $\mu\text{g}$  protein, were mixed with 20  $\mu\text{L}$  of water, 200  $\mu\text{L}$  of 10 mM Tris, 10 mM  $\text{CaCl}_2$ , 100 mM NaCl, pH 8.0 buffer, and 20  $\mu\text{L}$  of NOBA (0.32 mM final concentration). Plates were incubated at 37°C, and the change in absorbance at 425 nm was recorded after 20 min in a microplate reader (Awareness Technology).

### **Proteolytic activity**

Proteolysis was determined upon azocasein (Sigma-Aldrich) as described by *Wang et al. (2004)*. Twenty  $\mu\text{g}$  of venoms were diluted in 20  $\mu\text{L}$  of 25 mM Tris, 0.15 M NaCl, 5 mM  $\text{CaCl}_2$ , pH 7.4 buffer, added to 100  $\mu\text{L}$  of azocasein (10 mg/mL) and incubated for 90 min at 37°C. The reaction was stopped by adding 200  $\mu\text{L}$  of 5% trichloroacetic acid. After centrifugation, 100  $\mu\text{L}$  of supernatants were mixed with an equal volume of 0.5 M NaOH, and absorbances were recorded at 450 nm. Experiments were carried out in triplicate.

108

### 109 **L-amino acid oxidase activity**

110 L-amino acid oxidase (LAAO) activity was determined by adding various concentrations  
 111 of venom (2.5-20 µg) in 10 µL of water to 90 µL of a reaction mixture containing 250 mM L-  
 112 Leucine, 2 mM *o*-phenylenediamine, and 0.8 U/mL horseradish peroxidase, in 50 mM Tris, pH  
 113 8.0 buffer, in triplicate wells of a microplate (*Kishimoto et al., 2001*). After incubation at 37°C for  
 114 60 min, the reaction was stopped with 50 µL of 2 M H<sub>2</sub>SO<sub>4</sub>, and absorbances were recorded at  
 115 492 nm.

116

### 117 **Cytotoxic activity**

118 Cytotoxic activity was assayed on murine skeletal muscle C2C12 myoblasts (ATCC CRL-  
 119 1772) as described by *Lomonte et al. (1999)*. Venom (40 µg) was diluted in assay medium  
 120 (Dulbecco's Modified Eagle's Medium [DMEM] supplemented with 1% fetal calf serum [FCS]),  
 121 and added to subconfluent cell monolayers in 96-well plates, in 150 µL, after removal of growth  
 122 medium (DMEM with 10% FCS). Controls for 0 and 100% toxicity consisted of assay medium,  
 123 and 0.1% Triton X-100 diluted in assay medium, respectively. After 3 hr at 37 °C, a supernatant  
 124 aliquot was collected to determine the lactic dehydrogenase (LDH; EC 1.1.1.27) activity released  
 125 from damaged cells, using a kinetic assay (Wiener LDH-P UV). Experiments were carried out in  
 126 triplicate.

127

### 128 **ACE inhibitory activity**

129 The angiotensin-converting enzyme (ACE) inhibitory activity of fraction 4 from the  
 130 HPLC separation (see [Table 1](#)), which was identified as a bradykinin-potentiating peptide-like  
 131 component, was assayed by the method of *Cushman and Cheung (1971)* with some modifications  
 132 (*Kim et al., 1999*). Various concentrations of the fraction, diluted in 20 µL, were added to 100 µL

of 10 mM N-hippuryl-His-Leu substrate diluted in 2 mM potassium phosphate, 0.6 M NaCl, pH 8.3 buffer, and 5 mU of ACE (EC 3.4.15.1; 5.1 UI/mg) diluted in 50% glycerol. The reaction was incubated at 37°C for 30 min, and stopped by adding 200 µL of 1 N HCl. The produced hippuric acid was extracted by vigorous stirring for 10 sec, followed by the addition of 600 µL of ethyl acetate, and centrifugation for 10 min at 4000 ×g. An aliquot of 500 µL of organic phase was dried at 95°C for 10 min. The residue was dissolved in 1 mL of water and, after stirring, the absorbance was measured at 228 nm. The percentage of ACE inhibition (% ACEi) was determined using the following formula; % ACEi= (Abs Control - Abs sample)/(Abs control - Abs blank). Control absorbance corresponded to hippuric acid formed after the action of ACE, while blank absorbance was enzyme without substrate.

## Statistical analyses

The significance of differences between means was assessed by ANOVA, followed by Dunnett's test, when several experimental groups were compared with the control group, or by Student's t-test, when two groups were compared. Differences were considered significant if  $p < 0.05$ .

## RESULTS AND DISCUSSION

*B. punctatus* has been included in the 'red list', a report categorizing conservation status, as a threatened species ([Carrillo et al., 2005](#)). Very scarce information on its venom is available in the literature. In comparative studies of snake venoms from Colombia ([Otero et al., 1992](#)) and Ecuador ([Kuch et al., 1996](#)), respectively, this venom was found to induce local effects such as hemorrhage, edema, and myonecrosis, as well as systemic alterations such as defibrination, in similarity to venoms from other *Bothrops* species. Developments in proteomic techniques have



brought new possibilities to examine the detailed toxin composition of snake venoms, increasing knowledge on their evolution, toxicological properties, and correlation with clinical features of envenomings (Calvete, 2007, 2013; Fox and Serrano, 2008; Valente et al., 2009; Ohler et al., 2010). Therefore, the venom of *B. punctatus* was analyzed for the first time using proteomic tools, to gain a deeper understanding on its protein composition and relationships to toxic and enzymatic actions.

RP-HPLC of the crude venom resulted in the separation of 30 fractions (Fig.1C), which were further subjected to SDS-PAGE (Fig.1B), in-gel digestion of the excised bands, and MALDI-TOF-TOF analysis of the resulting peptides. The amino acid sequences obtained allowed the unambiguous assignment of 29 out of the 37 components analyzed, to known protein families of snake venoms (Table 1). Protein family relative abundances were estimated by integration of the chromatographic areas, combined with gel densitometric scanning. Results showed that the predominant proteins in this secretion are metalloproteinases (41.5%; SVMP), followed by C-type lectin/lectin-like proteins (16.7%; CTL), bradykinin-potentiating peptide-like peptides (10.7%; PEP), phospholipases A<sub>2</sub> of both the D49 (8.0%) and K49 (1.3%) subtypes (for a combined 9.3%; PLA<sub>2</sub>), serine proteinases (5.4%; SP), disintegrins (3.8%; DIS), L-amino acid oxidases (3.1%; LAO), vascular endothelial growth factor (1.7%; VEGF), and cysteine-rich secretory proteins (1.2%; CRISP), as summarized in Fig.2 and Table 1. An estimated 6.6% of the proteins remained unidentified, and owing to the scarcity of the venom, their assignment could not be further pursued.

A recent phylogenetic analysis of the genus *Bothrops* (*sensu lato*) by Fenwick et al. (2009) grouped *B. punctatus* within the same clade as *Bothrops atrox* and *Bothrops asper*. Since the proteomic profile of the venoms of the latter two species has been reported (Núñez et al., 2009; Alape-Girón et al., 2008), a comparison of their venom compositions, together with those of two other pitviper species distributed in Colombia, *Bothrops ayerbe* (Mora-Obando et al.,

183 [2014](#)) and *Bothriechis schlegelii* ([Lomonte et al., 2008](#)), was compiled ([Table 2](#)). Venoms from  
 184 these five species have been analyzed by the same methodological strategy, therefore allowing  
 185 reliable comparisons. The composition of *B. punctatus* venom resembles that of the other  
 186 *Bothrops* species listed in [Table 2](#) only in terms of their high content of metalloproteinases (41.5–  
 187 53.7%), but overall, its composition departs from the relative protein abundances observed in any  
 188 of the other four pitvipers. The high proportion of CTL proteins in *B. punctatus* is of note,  
 189 doubling the abundance observed in *B. atrox*, and close to that of *B. ayerbeii*, while in contrast  
 190 such proteins are expressed only in trace amounts in *B. asper*, and have not been detected in *B.*  
 191 *schlegelii* ([Table 2](#)). Further, *B. punctatus* venom presents a modest amount of VEGF (1.7%),  
 192 which has not been found in any of the venoms listed in [Table 2](#). In similarity with the venom of  
 193 the arboreal snake *B. schlegelii*, but also with the terrestrial species *B. ayerbeii*, the venom of *B.*  
 194 *punctatus* presents a high content of BPP-like peptides, strikingly differing from *B. asper* and *B.*  
 195 *atrox* venoms in this regard. The possible trophic relevance of these vasoactive peptides among  
 196 viperids remains elusive, and no clear correlations with prey types or habitats have been disclosed  
 197 thus far. BPPs are oligopeptides of 5–14 amino acid residues, rich in proline residues and often  
 198 presenting a pyroglutamate residue, which display bradykinin-potentiating activity. Their  
 199 pharmacological effect is related to the inhibition of angiotensin I-converting enzyme (ACE)  
 200 ([Janzer et al., 2007](#)). Peak 4 of the HPLC separation of *B. punctatus* venom components ([Fig.1C](#))  
 201 was identified as a BPP ([Table 1](#)), and its inhibitory activity on ACE was confirmed, showing a  
 202 half-maximal inhibition of this enzyme at 0.9 mg/mL ([Fig.3A](#)). Interest in snake venom BPPs  
 203 stems from their potential in the development of hypotensive drugs, as exemplified by Captopril®.  
 204 Overall, the comparison of *B. punctatus* venom with those of other pitvipers distributed in  
 205 Colombia ([Table 2](#)) highlights the remarkable divergence of compositional profiles that have  
 206 arisen through the evolution and diversification of snakes ([Casewell et al., 2013](#)).

207 The protein composition of *B. punctatus* venom correlates with the enzymatic activities  
 208 assayed, as well as with those described in earlier studies (*Otero et al., 1992; Kuch et al., 1996*).  
 209 L-amino acid oxidase (*Fig.3C*), proteolytic (*Fig.4A*), and PLA<sub>2</sub> (*Fig.4B*) activities of this venom  
 210 were corroborated. Interestingly, its proteolytic activity was higher than that of *B. asper* venom  
 211 (*Fig.4A*), and this might be related to the stronger hemorrhagic potency that was reported for *B.*  
 212 *punctatus* venom in comparison to *B. asper* venom (*Otero et al., 1992*). Hemorrhage induced by  
 213 viperid venoms is mainly dependent on the proteolytic action of SVMPs upon the  
 214 microvasculature and its extracellular matrix support (*Bjarnason and Fox, 1994; Gutiérrez et al.,*  
 215 *2005*), and this effect can be enhanced by venom components affecting haemostasis, such as  
 216 procoagulant SPs with thrombin-like activity, or some CTL components and disintegrins that  
 217 potently interfere with platelets, among others (*Gutiérrez et al., 2009; Calvete et al., 2005*).  
 218 Considering that the proportion of SVMPs is lower in *B. punctatus* than in *B. asper* venom (*Table*  
 219 *2*), the higher hemorrhagic action reported for the former (*Otero et al., 1992*) suggests that its  
 220 abundant CTL components (16.7%) might include toxins that affect platelets, a hypothesis that  
 221 deserves future investigation. On the other hand, the PLA<sub>2</sub> activity of *B. punctatus* venom was  
 222 lower than that of *B. asper* (*Fig.4B*), in agreement with their corresponding relative contents of  
 223 these enzymes (*Table 2*). However, a major contrast was evidenced in the cytotoxic activity of  
 224 these two venoms upon myogenic cells in culture, *B. punctatus* being essentially devoid of this  
 225 effect, while *B. asper* causing overt cytolysis and LDH release under identical conditions  
 226 (*Fig.4C*). Since cytolysis of myogenic cells, an *in vitro* correlate for *in vivo* myotoxicity  
 227 (*Lomonte et al., 1999*), has been shown to be mediated mainly by basic PLA<sub>2</sub>s in the case of  
 228 viperid venoms (*Gutiérrez & Lomonte, 1995; Lomonte & Rangel, 2012*), this finding anticipates  
 229 that the catalytically active (D49) PLA<sub>2</sub>s present in *B. punctatus* venom are likely to belong to the  
 230 acidic type of these enzymes, which despite frequently having higher enzymatic activity than  
 231 their basic counterparts, usually display very low, or even no toxicity (*Fernández et al., 2010*);

232 [Van der Laat et al., 2013](#)). In contrast, the venom of *B. asper* is rich in basic D49 and K49  
233 PLA<sub>2</sub>s/PLA<sub>2</sub> homologues with strong cytolytic and myotoxic effects ([Angulo & Lomonte, 2005](#),  
234 [2009](#)) that would explain the present findings. Although at least one PLA<sub>2</sub> component of *B.*  
235 *punctatus* venom was shown to belong to the K49 type of catalytically-inactive, basic PLA<sub>2</sub>  
236 homologues (fraction 23-25a; [Table 1](#)), its low abundance (1.3%) in the venom would be in  
237 agreement with the observed lack of cytotoxicity ([Fig.4C](#)).

238 In summary, the general compositional profile of *B. punctatus* venom was obtained  
239 through the analytical strategy known as 'snake venomomics'. The present data add to the growing  
240 body of knowledge on the remarkable diversity of compositional strategies in snake venom  
241 'cocktails', in spite of the reduced number of gene families that encode their proteins/toxins  
242 ([Casewell et al., 2013](#); [Calvete, 2013](#)). Due to the key adaptive role of venoms, this knowledge,  
243 in combination with toxicological, ecological, and natural history information, could lead to a  
244 deeper understanding of the evolutionary trends and selective advantages conferred by particular  
245 venom compositions in the divergence of snakes. In addition, compositional data may offer a  
246 more comprehensive basis to foresee the features of envenomings by this pitviper species, largely  
247 unreported in the literature.

248

## 249 ACKNOWLEDGMENTS

250 We thank Leidy Gómez, Paola Rey, and Wan-Chih Tsai for their valuable collaboration in  
251 the laboratory.

252

## 253 Funding

254 This work was funded by grants obtained from Universidad de Antioquia Sostenibilidad  
255 (2013-2014), and from Vicerrectoría de Investigación, Universidad de Costa Rica (project  
256 "Network for proteomic characterization of snake venoms of medical and biological relevance in

Latin America"; 741-B3-760). The Proteomics Laboratory of the Instituto Clodomiro Picado is partially supported by the Vicerrectoría de Investigación, UCR. Maritza Fernández received a Young Researcher Fellowship from COLCIENCIAS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Competing Interests

Bruno Lomonte is an Academic Editor of PeerJ.

## Author Contributions

Maritza Fernández and Andrés Pereáñez performed the experiments, analyzed the data, and wrote the paper. Vitelbina Núñez conceived and designed the experiments, analyzed the data, and wrote the paper. Bruno Lomonte performed the mass spectrometry analyses, analyzed the data, and revised the paper.

# 270 REFERENCES

- 271 **Alape-Girón A, Sanz L, Escolano J, Flores-Díaz M, Madrigal M, Sasa M, Calvete JJ. 2008.**  
272 Snake venomomics of the lancehead pit viper *Bothrops asper*: geographic, individual, and  
273 ontogenetic variations. *Journal of Proteome Research* **7**: 3556-3571.
- 274 **Angulo Y, Lomonte B. 2005.** Differential susceptibility of C2C12 myoblasts and myotubes to  
275 group II phospholipase A<sub>2</sub> myotoxins from crotalid snake venoms. *Cell Biochemistry and*  
276 *Function* **23**: 307-313.
- 277 **Angulo Y, Lomonte B. 2009.** Biochemistry and toxicology of toxins purified from the venom of  
278 the snake *Bothrops asper*. *Toxicon* **54**: 949-957.
- 279 **Bjarnason JB, Fox JW. 1994.** Hemorrhagic metalloproteinases from snake venoms.  
280 *Pharmacology and Therapeutics* **62**: 325-372.
- 281 **Calvete JJ. 2011.** Proteomic tools against the neglected pathology of snake bite envenoming.  
282 *Expert Reviews on Proteomics* **8**: 739-758.
- 283 **Calvete JJ. 2013.** Snake venomomics: from the inventory of toxins to biology. *Toxicon* **75**: 44-62.
- 284 **Calvete JJ, Juárez P, Sanz L. 2007.** Snake venomomics, strategy and applications. *Journal of Mass*  
285 *Spectrometry* **42**: 1405-1414.
- 286 **Calvete JJ, Marcinkiewicz C, Monleón D, Esteve V, Celda, Juárez P, Sanz L. 2005.** Snake  
287 venom disintegrins: evolution of structure and function. *Toxicon* **45**: 1063-1074.
- 288 **Campbell JA, Lamar WW. 2004.** *The Venomous Reptiles of the Western Hemisphere*. Ithaca,  
289 New York: Cornell University Press.
- 290 **Carrillo E, Aldás S, Altamirano MA, Ayala-Varela F, Cisneros-Heredia DF, Endara A,**  
291 **Márquez C, Morales M, Nogales-Sornosa F, Salvador P, Torres ML, Valencia J,**  
292 **Villamarín-Jurado F, Yáñez-Muñoz MH, Zárate P. 2005.** *Lista Roja de los Reptiles del*  
293 *Ecuador*. Quito, Ecuador: Fundación Novum Milenium, Ministerio de Educación y Cultura.

- 294 **Casewell NR, Wüster W, Vonk FJ, Harrison RA, Fry BG. 2013.**Complex cocktails: the  
295 evolutionary novelty of venoms. *Trends in Ecology and Evolution*, **28**: 219-229.
- 296 **Cushman DW, Cheung HS. 1971.** Spectrophotometric assay and properties of the angiotensin-  
297 converting enzyme of rabbit lung. *Biochemical Pharmacology* **20**: 1637-1648.
- 298 **Daza JM, Quintana JC, Otero R. 2005.** *Bothrops punctatus* (Chocoan forest pitviper)  
299 *Herpetological Review* **36**: 338.
- 300 **Fenwick AM, Ronald L, GutberleT JR, Jennafer AE, Parkinson CL. 2009.** Morphological  
301 and molecular evidence for phylogeny and classification of South American pitvipers, genera  
302 *Bothrops*, *Bothriopsis*, and *Bothrocophias* (Serpentes: *Viperidae*). *Zoological Journal of the*  
303 *Linnean Society* **156**: 617-640.
- 304 **Fernández J, Gutiérrez JM, Angulo Y, Sanz L, Juárez P, Calvete JJ, Lomonte B. 2010.**  
305 Isolation of an acidic phospholipase A<sub>2</sub> from the venom of the snake *Bothrops asper* of Costa  
306 Rica: biochemical and toxicological characterization. *Biochimie* **92**: 273-283.
- 307 **Fox JW, Serrano SMT. 2008.** Exploring snake venom proteomes: multifaceted analyses for  
308 complex toxin mixtures. *Proteomics* **8**: 909-920.
- 309 **Gutiérrez JM, Lomonte B. 1995.** Phospholipase A<sub>2</sub> myotoxins from *Bothrops* snake venoms.  
310 *Toxicon* **33**: 1405-1424.
- 311 **Gutiérrez JM, Rucavado A, Escalante T, Díaz C. 2005.** Hemorrhage induced by snake venom  
312 metalloproteinases: biochemical and biophysical mechanisms involved in microvessel  
313 damage. *Toxicon* **45**: 997-1011.
- 314 **Gutiérrez JM, Escalante T, Rucavado A. 2009.** Experimental pathophysiology of systemic  
315 alterations induced by *Bothrops asper* snake venom. *Toxicon* **54**: 976-987.
- 316 **Holzer M, Mackessy SP. 1996.** An aqueous endpoint assay of snake venom phospholipase A<sub>2</sub>.  
317 *Toxicon* **34**: 1149-1155.

- 318 **Ianzer D, Santos RA, Etelvino GM, Xavier CH, de Almeida Santos J, Mendes EP, Machado**  
319 **LT, Prezoto BC, Dive V, de Camargo AC. 2007.** Do the cardiovascular effects of  
320 angiotensin-converting enzyme (ACE) I involve ACE-independent mechanisms? new  
321 insights from proline-rich peptides of *Bothrops jararaca*. *Journal of Pharmacology and*  
322 *Experimental Therapeutics* **322**: 795-805.
- 323 **Kim YK, Yoon S, Yu DY, Lönnnerdal B, Chung BH. 1999.** Novel angiotensin-I-converting  
324 enzyme inhibitory peptides derived from recombinant human alpha s1-casein expressed in  
325 *Escherichia coli*. *Journal of Dairy Research* **66**: 431-439.
- 326 **Kishimoto M, Takahashi T. 2001.** A spectrophotometric microplate assay for L-amino acid  
327 oxidase. *Analytical Biochemistry* **298**: 136-139.
- 328 **Kuch U, Mebs D, Gutiérrez JM, Freire A. 1996.** Biochemical and biological characterization  
329 of Ecuadorian pitviper venoms (genera *Bothriechis*, *Bothriopsis*, *Bothrops* and *Lachesis*).  
330 *Toxicon* **34**: 714-717.
- 331 **Lomonte B, Rangel J. 2012.** Snake venom Lys49 myotoxins: from phospholipases A<sub>2</sub> to non-  
332 enzymatic membrane disruptors. *Toxicon* **60**: 520-530.
- 333 **Lomonte B, Angulo Y, Rufini S, Cho W, Giglio JR, Ohno M, Daniele JJ, Geoghegan P,**  
334 **Gutiérrez JM. 1999.** Comparative study of the cytolytic activity of myotoxic  
335 phospholipases A<sub>2</sub> on mouse endothelial (tEnd) and skeletal muscle (C2C12) cells *in vitro*.  
336 *Toxicon* **37**: 145-158.
- 337 **Lomonte B, Escolano J, Fernández J, Sanz L, Angulo Y, Gutiérrez JM, Calvete JJ. 2008.**  
338 Snake venomomics and antivenomics of the arboreal neotropical pitvipers *Bothriechis lateralis*  
339 and *Bothriechis schlegelii*. *Journal of Proteome Research* **7**: 2445-2457.
- 340 **Lomonte B, Tsai WC, Ureña-Díaz JM, Sanz L, Mora-Obando D, Sánchez EE, Fry BG,**  
341 **Gutiérrez JM, Gibbs HL, Calvete JJ. 2014.** Venomomics of New World pit vipers: genus-



wide comparisons of venom proteomes across *Agkistrodon*. *Journal of Proteomics* **96**: 103-116.

**Mora-Obando D, Guerrero-Vargas J, Prieto-Sánchez R, Beltrán J, Rucavado A, Sasa M, Gutiérrez JM, Ayerbe S, Lomonte B. 2014.** Proteomic and functional profiling of the venom of *Bothrops ayerbei* from Cauca, Colombia, reveals striking interspecific variation with *Bothrops asper* venom. *Journal of Proteomics* **96**: 159-172.

**Núñez V, Cid P, Sanz L, De La Torre P, Angulo Y, Lomonte B, Gutiérrez JM, Calvete JJ. 2009.** Snake venomomics and antivenomics of *Bothrops atrox* venoms from Colombia and the Amazon regions of Brazil, Perú and Ecuador suggest the occurrence of geographic variation of venom phenotype by a trend towards paedomorphism. *Journal of Proteomics* **73**: 57-78.

**Georgieva D, Ohler M, Seifert J, von Bergen M, Arni RK, Genov N, Betzel C. 2010.** Snake venomomic of *Crotalus durissus terrificus* - correlation with pharmacological activities. *Journal of Proteome Research* **9**: 2302-216.

**Otero R. 1994.** *Manual de Diagnóstico y Tratamiento del Accidente Ofídico*. Medellín, Colombia: Editorial Universidad de Antioquia.

**Otero R, Osorio RG, Valderrama R, Giraldo CA. 1992.** Efectos farmacológicos y enzimáticos de los venenos de serpientes de Antioquia y Chocó (Colombia). *Toxicon* **30**: 611-620.

**Paredes AE. 2012.** *Informe del Evento Accidente Ofídico. Vigilancia y Control en Salud Pública*. Colombia: Instituto Nacional de Salud.

**Valente RH, Guimarães PR, Junqueira M, Neves-Ferreira AG, Soares MR, Chapeaurouge A, Trugilho MR, León IR, Rocha SL, Oliveira-Carvalho AL, Wermelinger LS, Dutra DL, Leão LI, Junqueira-de-Azevedo IL, Ho PL, Zingali RB, Perales J, Domont GB. 2009.** *Bothrops insularis* venomomics: a proteomic analysis supported by transcriptomic-generated sequence data. *Journal of Proteomics* **72**: 241-255.

- 366 **Van der Laat M, Fernández J, Durban J, Villalobos E, Camacho E, Calvete JJ, Lomonte B.**  
367 **2013.** Amino acid sequence and biological characterization of BlatPLA<sub>2</sub>, a non-toxic acidic  
368 phospholipase A<sub>2</sub> from the venom of the arboreal snake *Bothriechis lateralis* from Costa  
369 Rica. *Toxicon* **73**: 71-80.
- 370 **Wang WJ, Shih CH, Huang TF. 2004.** A novel P-I class metalloproteinase with broad substrate-  
371 cleaving activity, agkislysin, from *Agkistrodon acutus* venom. *Biochemical and Biophysical*  
372 *Research Communications* **324**: 224-230.

## Figure legends

**Figure 1. Separation of *Bothrops punctatus* (A) venom proteins by RP-HPLC (B) and SDS-PAGE (C).** Venom was fractionated on a C<sub>18</sub> column (C) by applying an acetonitrile gradient from 0 to 70% (dashed line), as described in Methods. Each fraction was analyzed by SDS-PAGE (B) under non-reducing (top gels) or reducing (bottom gels) conditions. Molecular weight markers (M) are indicated in kDa, at the left. Tryptic digests of the excised protein bands were characterized by MALDI-TOF/TOF, as summarized in Table 1. The photograph of *B. punctatus* was obtained with permission from [www.tropicalherping.com](http://www.tropicalherping.com).

**Figure 2. Composition of *Bothrops punctatus* venom according to protein families, expressed as percentages of the total protein content.** SP: serine proteinase; PLA<sub>2</sub>: phospholipase A<sub>2</sub>; CRISP: cysteine-rich secretory protein; DIS: disintegrin; PEP: bradykinin-potentiating peptide-like (BPP-like); LAO: L-amino acid oxidases; SVMP: metalloproteinase; VEGF: vascular endothelium growth factor; CTL: C-type lectin/lectin-like; UNK: unknown/unidentified.

**Figure 3. *Bothrops punctatus* venom activities.** (A) Inhibition of angiotensin-converting enzyme (ACE) by peak 4 of *B. punctatus* venom, identified as a BPP-like peptide (Table 1). Each point represents the mean  $\pm$  SD of three replicates. (B) L-amino acid oxidase activity of *B. punctatus* venom. Each point represents the mean  $\pm$  SD of three replicates.

**Figure 4. Proteolytic (A), phospholipase A<sub>2</sub> (B), and cytotoxic (C) activities of *Bothrops punctatus* venom, compared to the venom of *Bothrops asper*.** Proteolytic activity was determined on azocasein, using 20  $\mu$ g of each venom. Phospholipase A<sub>2</sub> activity was determined

398 on 4-nitro-3-octanoyloxy-benzoic acid, using 20  $\mu\text{g}$  of each venom. Cytotoxic activity was  
 399 determined on C2C12 murine myoblasts, using 40  $\mu\text{g}$  of each venom, as described in Methods.  
 400 Bars represent mean  $\pm$  SD of three replicates. For each activity, differences between the two  
 401 venoms were significant ( $p < 0.05$ ).

402

# **Table 1** (on next page)

Assignment of the RP-HPLC isolated fractions of Bothrops punctatus venom to protein families by MALDI-TOF-TOF of selected peptide ions from in-gel trypsin-digested protein bands.

**Table 1:** Assignment of the RP-HPLC isolated fractions of *Bothrops punctatus* venom to protein families by MALDI-TOF-TOF of selected peptide ions from in-gel trypsin-digested protein bands.

Peak	%	Mass (kDa)	Peptide ion	MS/MS-derived amino acid sequence <sup>+</sup>		Protein family; ~ related protein	
			m/z		z		
1	0.2		-	-	-	-	unknown
2	0.3		-	-	-	-	unknown
3	1.6		-	-	-	-	unknown
4	10.7	-	967.5		1	ZBWAPVBK	BPP-like; ~ Q7T1M3
5	0.8	▼ 10	2259.1		1	XARGDDM <sup>o</sup> DDY	Disintegrin; ~ Q7SZD9
			2051.0		1	CNGXSAGCPR	
			2459.0		1	XRPGABCAEGXC	
						CDBCR	
						EAGEECDGTPG	
						NPCCDAATCK	
6	3.0	▼ 10	1902.9		1	GDDMDDYCNGX	Disintegrin; ~ Q0NZX5
			2243.1		1	SAGCPR	
			2051.0		1	XARGDDMDDYC	
			2459.1		1	NGXSAGCPR	
						XRPGABCAEGXC	
						CDBCR	
						EAGEECDGTPG	
						NPCCDAATCK	
7	0.3		-	-	-	-	unknown
8	1.7	▼ 11	2062.0		1	CGGCCTDESXEC	VEGF; ~ Q90X23
			3134.9		1	TATGBR	
						ETXVSXXEEHPD	
						EVSHXFRPSCVTA	
						XR	
9	1.2	▼ 22 ■ 18	2526.1		1	SGPPCGDCPSAC	CRISP; ~ Q7ZT99
			1537.8		1	DNGXCTNPCTK	
			1828.9		1	MEWYPEAAANA	
						ER	
						YFYVCBYCPAGN	
						MR	

10a	0.4	▼38	1561.9	1	SVPNDDEEXRYP K	Serine proteinase; ~ Q5W960
10b	0.2	▼29 ■28	1206.8 1683.2 2534.5 1069.8 1512.8 3387.8	1 1 1 1 1 1	XMGWGTXSPTK TYTBWDBDXMX XR VSYPDVPHCANX NXXDYEVCR FXVAXYTSR VXGGDECXNE HR DSCBGDSGGPXX CNGBFBGXXSW GVHPCGBR	Serine proteinase; ~ Q072L6
10c	0.3	▼12 ■22	-	-	-	unknown
11	1.5	▼28 ■20	1288.7 1190.7 2305.4 1140.6 2477.5 2477.4	1 1 1 1 1 1	NFBMBXGVHSC XMGWGTXSPTK AAYPWBPVSSTT XCAGXXBGGK VSDYTEWVK VSNSEHXAPXSX PSSPPSVGSVCR VXGGDECXNE HR	Serine proteinase; ~ Q072L6
12a	1.8	▼35	1083.7	1	FAXFXYPGR	Serine proteinase; ~ Q6IWF1
12b	0.4	▼29 ■22	1517.9 1499.8 2294.3 1279.7 2889.7 1083.7	1 1 1 1 1 1	NDDAXDBDXMX VR VVGDECXNE HR TNPDVPHCANXN XXDDAVCR AAYPEXPAEYR XDSPVSNSEHXA PXSXPSSPPSVGS VCR FAXFXYPGR	Serine proteinase; ~ Q5W959
13-15	0.8		-	-	-	unknown
16	3.1	▼16 ■16	1505.7 934.6 1966.1	1 1 1	CCFVHDCCYGK YWFYGA YXSYGCYCGWG	Phospholipase A <sub>2</sub> , D49; ~ P86389

			2064.1	1	GXGBPK	
			2027.2	1	DATDRCCFVHDC	
			2626.4	1	CYGK	
			1786.0	1	DNBDTYDXBYW	
					FYGAK	
					XDXYTYSBETGD	
					XVCGGDDPCBK	
					BXCECDRVAATC	
					FR	
17a	0.4	▼ 14 ■ 21	1928.9	1	DCPPDWSSYEGH	C-type lectin/lectin-like; ~ P22030
					CYR	
17b	1.7	▼ 15 ■ 16	2027.1	1	DNBDTYDXBYW	Phospholipase A <sub>2</sub> , D49; ~ C9DPL5
					FYGAK	
17c	0.4	■ 13	1720.8	1	E <sup>pa</sup> NGDVVCGGDD	Phospholipase A <sub>2</sub> , D49; ~ P86389
			1505.7	1	PCBK	
			2064.0	1	CCFVHDCCYGK	
					DATDRCCFVHDC	
					CYGK	
18	2.8	▼ 13	2064.0	1	DATDRCCFVHDC	Phospholipase A <sub>2</sub> , D49; ~ Q9I968
19	0.3		-	-	-	unknown
20	6.2	▼ 13 ■ 19	1928.9	1	DCPSDWSPYEGH	C-type lectin/lectin-like; ~ Q9PS06
					CYR	
21	0.8		-	-	-	unknown
22a	0.9	■ 120	1537.8	1	ACSNGBCVDVNR	Metalloproteinase; ~ Q8AWI5
			1269.7	1	AS	
					SAECTDRFBR	
22b	3.1	▼ 53 ■ 48	3185.9	1	VVXVGAGMSGX	L-amino acid oxidase; ~ Q6TGQ9
			2605.5	1	SAAYVXANAGHB	
			2271.3	1	VTVXEASER	
			1388.8	1	BFGXBXNEFSBE	
			1352.8	1	NENAWYFXK	
					XYFAGEYTABA	
					GWXDSTXK	
					BFWEDDGXHGG	
					K	
					SAGBXYESXBK	
22c	0.9	▼ 13	1636.0	1	NXBSSDXYAWXG	C-type lectin/lectin-like; ~ P22029
			1928.9	1	XR	
					DCPPDWSSYEGH	



23-25a	1.3	▼13	1533.7	1	CYR SYGAYGCNCGVX GR	Phospholipase A <sub>2</sub> , K49; ~ Q9PVE3
23-25b	1.1	▼28, ■20	1279.7 14.997 2294.1	1 1 1	AAYPEXPAEYR VVGGEDECNXNE HR TNPDPVPHCANXN XXDDAVCR	Serine proteinase; ~ Q5W959
23-25c	0.9	▼13, ■19	1635.8	1	NXBSSDXYAWXG XR	C-type lectin/lectin- like; ~ P22029
26	14.4	▼23 ■42	2040.2 1114.6 2257.3 1828.0	1 1 1 1	YXYXDXXTGV EXWSNK XHBMVNXMK DXXNVBPAAPBT XDSFGEWR YVEXFXVVDHG MFMK	Metalloproteinase; ~ P86976
27	2.0		-	-	-	unknown
28a	18.3	▼46 ■42	1552.7 2953.3 2154.2	1 1 1	VCSNGHCVDVAT AY ASM <sup>ox</sup> SECDPAEH CTGBSSECPADV HK XTVBPDVDYTXN SFAEWR	Metalloproteinase; ~ Q8QG88
28b	2.1	■21	3261.7 1457.0	1 1	TDXVSPPVCGNY FVEVGEDCDCGS PATCR XVXVADYXM <sup>ox</sup> F XK	Metalloproteinase; ~ O93517
28c	6.2	▼14	1635.9 1193.6	1 1	NXBSSDXYAWXG XR TTDNBWWSR	C-type lectin-like; ~ P22029
29a	3.2	▼46	2154.2 1609.9 1775.0	1 1 1	XTVBPDVDYTXN SFAEWR XYEXVNTXNVX YR YVEFFXVVDBG VTK	Metalloproteinase; ~ Q8QG88
29b	2.1	▼14	992.5	1	MNWADAER	C-type lectin/lectin-

			1928.8	1	DCPPDWSSYEGH	like; ~ M1V359
			1842.9	1	CYR	
					MNWADAERFCSE	
					QAK	
30	2.6	▼38	1327.8	1	YXEXVXVADHR	Metalloproteinase; ~ Q8AWX7

\* Cysteine residues determined in MS/MS analyses are carbamidomethylated. X: Leu/Ile; B: Lys/Gln; <sup>ox</sup>: oxidized; <sup>pa</sup>: propionamide; ▼: reduced, or ■: non-reduced SDS-PAGE mass estimations, in kDa. Abbreviations for protein families as in [Figure 2](#).

## Table 2<sub>(on next page)</sub>

Comparison of the venom composition of *Bothrops punctatus* with venoms from pitviper species distributed in Colombia

**Table 2.** Comparison of the venom composition of *Bothrops punctatus* with venoms from pitviper species distributed in Colombia.\*


Protein family	Snake species				
	<i>Bothrops punctatus</i> <sup>a</sup>	<i>Bothrops atrox</i> <sup>b</sup>	<i>Bothrops asper</i> <sup>c</sup>	<i>Bothriechis schlegelii</i> <sup>d</sup>	<i>Bothrops ayerbei</i> <sup>e</sup>
Metalloproteinase	41.5	48.5	44.0	17.7	53.7
Phospholipase A <sub>2</sub>	9.3	24.0	45.1	43.8	0.7
Serine proteinase	5.4	10.9	10.9	5.8	9.3
BPP-like	10.7	0.3	-	13.4	8.3
CRISP	1.2	2.6	0.1	2.1	1.1
C-type lectin/lectin-like	16.7	7.1	0.5	-	10.1
VEGF	1.7	-	-	-	-
L-amino acid oxidase	3.1	4.7	4.6	8.9	3.3
Disintegrin	3.8	1.7	1.4	-	2.3
Kazal type inhibitor	-	-	-	8.3	-
Phosphodiesterase	-	-	-	-	0.7
Nerve growth factor	-	-	-	-	0.1
unknown	6.6	-	-	-	1.7
<b>Number of families</b>	<b>9</b>	<b>8</b>	<b>7</b>	<b>7</b>	

\* Although *B. asper* and *B. schlegelii* are found in Colombia, data correspond to venoms from specimens found in Costa Rica.

<sup>a</sup> present work; <sup>b</sup> Núñez *et al.* (2009); <sup>c</sup> Alape-Girón *et al.* (2008), specimens of Pacific versant; <sup>d</sup> Lomonte *et al.* (2008); <sup>e</sup> Mora-Obando *et al.* (2014).


# Figure 1

Separation of *Bothrops punctatus* (A) venom proteins by RP-HPLC (B) and SDS-PAGE (C).




## Figure 2

Composition of *Bothrops punctatus* venom according to protein families, expressed as percentages of the total protein content.



# Figure 3

*Bothrops punctatus* venom activities.



# Figure 4

Proteolytic (A), phospholipase A2 (B), and cytotoxic (C) activities of *Bothrops punctatus* venom, compared to the venom of *Bothrops asper*.



